Drug Profile
Epoetin beta - Chugai
Alternative Names: EPOCH; Epogin; MarogenLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Chugai Pharmaceutical; Roche
- Class Antianaemics; Colony-stimulating factors; Recombinant erythropoietins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Anaemia
- Discontinued Chemotherapy-induced anaemia
Most Recent Events
- 12 Apr 2012 Discontinued - Preregistration for Chemotherapy-induced anaemia in Japan (SC)
- 30 Sep 2011 The Pharmaceutical Affairs Subcommittee of the Pharmaceutical Affairs and Food Sanitation Council recommends against approval of epoetin beta for Chemotherapy-induced anaemia in Japan
- 25 Jun 2011 FDA modifies dosage guidelines for Erythropoiesis-Stimulating Agents in patients with chronic kidney disease